Notice2022-00704
Notice of Award of a Single-Source Cooperative Agreement To Fund the All-India Institute for Medical Sciences, New Delhi (AIIMS, New Delhi)
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 14, 2022
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $2,000,000, with an expected total funding of approximately $10,000,000 over a five-year period, to AIIMS, New Delhi. The award will support research to estimate the incidence of influenza and other respiratory viruses (such as SARS-CoV-2) among working-age adults and other priority populations in India to strengthen the evidence base and inform influenza vaccine policy in India.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 10 (Friday, January 14, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 10 (Friday, January 14, 2022)]
[Notices]
[Page 2440]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-00704]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Single-Source Cooperative Agreement To Fund
the All-India Institute for Medical Sciences, New Delhi (AIIMS, New
Delhi)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award of approximately $2,000,000, with an expected total funding of
approximately $10,000,000 over a five-year period, to AIIMS, New Delhi.
The award will support research to estimate the incidence of influenza
and other respiratory viruses (such as SARS-CoV-2) among working-age
adults and other priority populations in India to strengthen the
evidence base and inform influenza vaccine policy in India.
DATES: The period for this award will be September 30, 2022, through
September 29, 2027.
FOR FURTHER INFORMATION CONTACT: Amy Yang, Ph.D., National Center for
HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, MS US8-1, Atlanta, GA
30329, Telephone: 404-718-8835, email: <a href="/cdn-cgi/l/email-protection#beddd1cccee1dbccced1e186868d8bfedddadd90d9d1c8"><span class="__cf_email__" data-cfemail="65060a17153a0017150a3a5d5d5650250601064b020a13">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: This single-source award will allow the
recipient to conduct research to estimate the incidence of influenza
and other respiratory viruses (such as SARS-CoV-2) among working-age
adults and other priority populations in India to strengthen the
evidence base and inform influenza vaccine policy in India.
AIIMS, New Delhi, is in a unique position to conduct this work, as
it is the only institution in India with the required scientific and
technical expertise to conduct multi-site cohort studies on influenza
and other respiratory viruses like SARS-CoV-2 which require robust
epidemiological and laboratory capacity and maintains the high research
standards required by CDC. AIIMS, New Delhi, is governmentally mandated
by the AIIMS Act of 1956 and operates autonomously as an institution of
national importance under the Ministry of Health and Family Welfare.
AIIMS, New Delhi, is the leader of basic, clinical, and translational
medical research in India.
Summary of the Award
Recipient: The All-India Institute for Medical Sciences, New Delhi
(AIIMS, New Delhi).
Purpose of the Award: The purpose of this award is to support
research to estimate the incidence of influenza and other respiratory
viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), among working-aged adults and other priority populations in
India to strengthen the evidence base to help inform influenza vaccine
policy in India. The recipient will set up a multi-center hospital-
based platform in India to estimate the disease and economic burden of
influenza- and COVID-19-associated hospitalization of working age
adults (18-60 years) in India. An additional goal is to increase
awareness about influenza burden and prevention methods among
clinicians and public health practitioners. This project aligns with
activities conducted under the CDC Influenza Division's International
Program to build the evidence base for better understanding the disease
and economic burden of influenza and to identify strategies for
influenza prevention, including vaccination in low- and middle-income
settings.
Amount of Award: $2,000,000 in Federal Fiscal Year (FYY) 2022
funds, and an estimated $2,000,000 for each subsequent 12-month budget
period over five years, subject to availability of funds.
Authority: This program is authorized under Public Health Service
Act, Section 307 (42 U.S.C. 242l).
Period of Performance: September 30, 2022 through September 29,
2027.
Dated: January 11, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2022-00704 Filed 1-13-22; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 14, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.